Unraveling the role of core promoter variation in triple-negative breast cancer: Study

TNBC is a particularly aggressive subtype of breast cancer, characterized by the absence of three key receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Approximately 10–20% of all breast cancers are TNBC. TNBC patients face a poorer prognosis due to the lack of specific drug targets. Therefore, the discovery of new factors influencing the development and progression of TNBC is crucial for improving patient outcomes.